Epigenetic Therapies and Technologies: World Market Prospects 2013-2023
How to find trends and revenue predictions for epigenetics
What does the future hold for epigenetic applications? Visiongain's new report gives you revenue predictions to 2023 for those therapies, technologies and diagnostic products. There you find sales data, R&D trends, opportunities and commercial prospects.
That analysis lets you assess forecasted sales at overall world market, submarket, product, regional and national level. You discover the potential of the industry and market for epigenetics, seeing where that field is heading.
Forecasts and other analyses to help you find the best opportunities
In our study you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (SWOT and STEP), business news, outlooks and developmental trends (R&D). You gain 70 tables, 47 charts and two research interviews.
Our work lets you investigate the most lucrative areas in that industry and market. Those technologies hold great promise.
The following sections show what you see in our updated report.
You discover prospects for the world market and submarkets
Along with revenue prediction for the overall world market, you see individual forecasts for three epigenetic submarkets to 2023:
Also, how will existing and expected products - Vidaza, Dacogen, Zolinza, Istodax, Belinostat and Faridak - perform at world level to 2023? You see forecasts and discussions for those drugs.
Our work also breaks the overall world forecast into leading geographical markets.
What prospects for leading regions and countries?
Developments worldwide will influence the market from 2013. There are many opportunities for healthcare companies large and small.
You discover individual revenue forecasts to 2023 for eight national markets and two regional blocks. Find relevant overall sales:
Research and development - see trends and possibilities
What's happening in epigenetic R&D? You see trends and outlooks there:
What affects the application of epigenetics?
Our report discusses issues and events affecting that science, industry and market from 2013 onwards:
Leading companies and market value
Overall world revenue for epigenetic applications will reach $2,518m in 2013, our report forecasts. The R&D pipeline is diverse and promising. That industry holds great potential for further investment, development and growth.
In our study you find discussions of these organisations and many others:
Nine ways Epigenetic Therapies and Technologies: World Market Prospects 2013-2023 helps you
To sum up, our investigation gives you the following knowledge on the topic:
That work gives independent analysis from our primary and secondary research. You receive business intelligence found only in our study, seeing where prospects are lucrative.
With our report you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions, saving time and getting you recognition for technological and commercial insight.
Ordering now lets you discover commercial prospects to 2023 for epigenetics
Visiongain's study is for everyone needing forward-looking analysis of pharmaceutical and diagnostic biotechnology. You find data, trends and predictions. Please ask for our report now.
What does the future hold for epigenetic applications? Visiongain's new report gives you revenue predictions to 2023 for those therapies, technologies and diagnostic products. There you find sales data, R&D trends, opportunities and commercial prospects.
That analysis lets you assess forecasted sales at overall world market, submarket, product, regional and national level. You discover the potential of the industry and market for epigenetics, seeing where that field is heading.
Forecasts and other analyses to help you find the best opportunities
In our study you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (SWOT and STEP), business news, outlooks and developmental trends (R&D). You gain 70 tables, 47 charts and two research interviews.
Our work lets you investigate the most lucrative areas in that industry and market. Those technologies hold great promise.
The following sections show what you see in our updated report.
You discover prospects for the world market and submarkets
Along with revenue prediction for the overall world market, you see individual forecasts for three epigenetic submarkets to 2023:
- Therapies
- Technologies
- Diagnostics.
Also, how will existing and expected products - Vidaza, Dacogen, Zolinza, Istodax, Belinostat and Faridak - perform at world level to 2023? You see forecasts and discussions for those drugs.
Our work also breaks the overall world forecast into leading geographical markets.
What prospects for leading regions and countries?
Developments worldwide will influence the market from 2013. There are many opportunities for healthcare companies large and small.
You discover individual revenue forecasts to 2023 for eight national markets and two regional blocks. Find relevant overall sales:
- US
- Canada
- Japan
- Germany, France, UK, Italy and Spain (EU5 countries)
- Europe
- Brazil, Russia, India and China (BRIC nations, grouped analysis).
Research and development - see trends and possibilities
What's happening in epigenetic R&D? You see trends and outlooks there:
- HDAC inhibitors
- DNMT inhibitors
- Treatments targeting other enzymes
- MiRNA therapy
- Diagnostics pipeline.
- New drug targets
- Biomarkers
- Bioinformatics
- Next generation sequencing.
What affects the application of epigenetics?
Our report discusses issues and events affecting that science, industry and market from 2013 onwards:
- Cancer research and treatment
- DNA hypomethylation in autoimmune diseases
- Neurodegenerative diseases
- Neurological disorders
- Understanding of epigenetic markers and mechanisms.
- Genomics, proteomics and metabolomics
- Translational research
- Licensing, outsourcing and academic collaborations
- Developments with stem cells
- Orphan indications and patient subpopulations
- Companion diagnostics and stratified medicine.
Leading companies and market value
Overall world revenue for epigenetic applications will reach $2,518m in 2013, our report forecasts. The R&D pipeline is diverse and promising. That industry holds great potential for further investment, development and growth.
In our study you find discussions of these organisations and many others:
- Celgene
- Eisai
- Merck & Co.
- Roche
- Astex Pharmaceuticals
- Exact Sciences
- Orion Genomics.
Nine ways Epigenetic Therapies and Technologies: World Market Prospects 2013-2023 helps you
To sum up, our investigation gives you the following knowledge on the topic:
- Forecasted revenues to 2023 for the overall world market and 3 submarkets - you discover prospects for the industry's future
- Predicted revenues of 6 products to 2023 - you find prospects for drugs, both existing brands and those awaiting launch
- Market forecasting to 2023 for US, Canada, Japan, Germany, France, UK, Spain, Italy, BRIC nations and Europe - you see national and regional outlooks
- Assessments of companies - you find activities, products, strategies and outlooks
- Review of R&D by technology and disease - you hear about progress in established and emerging research areas
- Opinions on the sector - you read our interviews with leaders in that industry
- Competition and opportunities influencing sales - you see what affects the future
- Discussions of what stimulates and restrains the industry and market - you explore business trends, drivers and restraints
- Prospects for established firms and those seeking to enter the sector - you assess needs, practices and outlooks for success.
That work gives independent analysis from our primary and secondary research. You receive business intelligence found only in our study, seeing where prospects are lucrative.
With our report you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions, saving time and getting you recognition for technological and commercial insight.
Ordering now lets you discover commercial prospects to 2023 for epigenetics
Visiongain's study is for everyone needing forward-looking analysis of pharmaceutical and diagnostic biotechnology. You find data, trends and predictions. Please ask for our report now.
1. EXECUTIVE SUMMARY
1.1 Epigenetic Therapies and Technologies: World Market Review
1.2 Report Contents
1.3 Research and Analysis Methods
2. AN INTRODUCTION TO EPIGENETICS
2.1 How is Epigenetics Defined?
2.1.1 Epigenetic Mechanisms
2.1.2 A Brief History of Epigenetic Research
2.2 The Links between Epigenetics and Disease
2.2.1 The Role of Lifestyle in Epigenetics
2.2.2 Epigenetics and Cancer
2.2.3 Epigenetics in Inherited Disorders
2.2.4 Epigenetics in Neurological Diseases
2.3 Epigenetics for Disease Diagnosis
2.3.1 Diagnosing for Breast Cancer
2.3.2 Colorectal Cancer: The Importance of Early Diagnosis
2.3.3 Diagnostics for Lung Cancer: Difficulty in Accessing Samples
2.3.4 Diagnostics for Prostate Cancer
2.4 The Use of Epigenetics in Treating Disease
2.4.1 DNA Methyltransferase (DNMT) Inhibitors
2.4.1.1 Myelodysplastic Syndromes (MDS)
2.4.2 Histone Deacetylase (HDAC) Inhibitors
2.4.2.1 Cutaneous T Cell Lymphoma (CTCL)
2.4.2.2 Peripheral T Cell Lymphoma (PTCL)
2.5 Drug Discovery and Development Tools Using Epigenetics
2.5.1 Bisulphite Screening for DNA Methylation
2.5.2 Chromatin Immunoprecipitation (ChIP) for Histone Modification
3. THE EPIGENETIC THERAPIES AND TECHNOLOGIES MARKET 2013-2023
3.1 The Epigenetic Therapies and Technologies Market 2011-2012
3.1.1 Leading Sectors of the Market 2011-2012
3.2 The Epigenetic Therapies and Technologies Market 2013-2023
3.2.1 The Epigenetic Therapies and Technologies Market: Overall Revenue Forecast 2013-2023
3.2.2 What Will Drive Revenue Growth for Epigenetic Therapies and Technologies?
3.2.3 Rising Importance for Diagnostics Revenue 2013-2023
3.3 Epigenetic Therapies Submarket 2013-2023
3.3.1 Epigenetic Therapies Submarket: Revenue Forecast 2013-2023
3.3.2 Factors Influencing Epigenetic Therapy Uptake and Revenues 2013-2023
3.4 Epigenetic Technologies Submarket 2013-2023
3.4.1 Epigenetic Technologies Submarket: Revenue Forecast 2013-2023
3.4.2 Epigenetic Technologies Submarket: Drivers and Restraints 2013-2023
3.5 Epigenetic Diagnostics Submarket 2013-2023
3.5.1 Epigenetic Diagnostics Submarket: Revenue Forecast 2013-2023
3.5.2 New Product Launches to Drive Growth 2013-2023
4. LEADING NATIONAL EPIGENETIC THERAPY AND TECHNOLOGY MARKETS 2013-2023
4.1 Leading National Markets for Epigenetic Therapies and Technologies 2011-2012
4.2 Leading National Markets: Revenue Forecasts 2013-2023
4.2.1 The Continued Dominance of Western Markets 2013-2023
4.3 The North American Market 2013-2023
4.3.1 The US: The World's Largest Market for Epigenetic Therapies and Technologies 2013-2023
4.3.2 Canada: Revenues 2013-2023
4.4 The European Market 2011-2012
4.4.1 Leading National Markets in Europe: Revenue Forecasts 2013-2023
4.4.2 Germany: Revenues 2013-2023
4.4.3 The UK: A Leading Market for Epigenetics Research
4.5 Japan: Recent Entry of the Epigenetic Therapies Market
4.6 Epigenetics in Emerging Markets
4.6.1 BRIC Nations: Rising Importance for Epigenetic Therapies and Technologies 2013-2023
5. EPIGENETIC THERAPIES MARKET 2013-2023
5.1 Changes to the Epigenetic Therapies Market 2013-2023
5.2 Vidaza: The First Epigenetic Therapy Approved
5.2.1 Vidaza: Strong Revenue Growth 2004-2011
5.2.2 Development as a Combination Therapy to Drive Growth
5.2.3 Vidaza: Revenue Forecast 2013-2023
5.3 Dacogen
5.3.1 Revenue Performance 2004-2011
5.3.2 Approval in the EU in 2012 to Drive Revenue Growth
5.3.3 Dacogen: Revenue Forecast 2013-2023
5.4 Zolinza
5.4.1 Zolinza as a Potential Treatment for Multiple Myeloma
5.4.2 Zolinza: Revenue Forecast 2013-2023
5.5 Istodax
5.5.1 US PTCL Approval
5.5.2 Istodax: Revenue Forecast 2013-2023
5.6 Rich Pipeline for HDAC Inhibitors in 2012
5.6.1 Belinostat: A Selective HDAC Inhibitor for PTCL
5.6.2 Faridak for Velcade-Refractory Multiple Myeloma
5.6.3 Entinostat (Syndax Pharmaceuticals)
5.6.4 Resminostat (4SC)
5.6.5 Pracinostat: The First Epigenetic Therapy Developed in Singapore
5.6.6 Mocetinostat Has Been Tested in More Than 12 Clinical Trials
5.6.7 Quisinostat (Centocor Research & Development)
5.6.8 Rocilinostat (Acetylon Pharmaceuticals)
5.6.9 CHR-3996 (Chroma Therapeutics)
5.6.10 Givinostat for Cancer, Autoimmune and Neurodegenerative Diseases
5.6.11 SHP-141 (Shape Pharmaceuticals)
5.6.12 EVP-0334 (EnVivo Pharmaceuticals/MethylGene)
5.6.13 4SC-202 (4SC)
5.6.14 Tefinostat (Chroma Therapeutics)
5.6.15 CXD101 (Celleron Therapeutics)
5.6.16 Repligen: Epigenetic Therapies for Orphan Neurodegenerative Indications
5.6.17 Abexinostat (Pharmacyclics/Servier)
5.7 DNMT Inhibitor Pipeline 2012
5.7.1 SGI-110: A Second Generation DNMT Inhibitor
5.8 Pipeline Treatments Targeting Other Epigenetic Enzymes 2012
5.8.1 EPZ-5676: The First Clinical-Stage HMT Inhibitor
5.8.2 Oryzon Genomics: Targeting LSD1
5.8.3 Salarius Pharmaceuticals
5.8.4 Resverlogix Advancing BET Protein Inhibitors
5.9 MiRNA Therapy Pipeline 2012
5.9.1 Miravirsen (Santaris Pharma) is the Only Clinical-Stage miRNA Therapy
5.9.2 MRX34 (Mirna Therapeutics)
5.9.3 Regulus Therapeutics Is Collaborating with Big Pharma Players
5.10 Leading Epigenetic Therapy Manufacturers and Developers 2012
5.10.1 Celgene: Market Leader 2011-2012
5.10.2 Eisai
5.10.3 Merck & Co.
5.10.4 TopoTarget: Assessing Drug Commercialisation Strategies
5.10.5 Syndax Pharmaceuticals
5.10.6 4SC
5.10.7 Astex Pharmaceuticals is an Experienced Epigenetic Therapy Developer
5.10.8 Curis is Developing Multi-Targeted Therapies
5.10.9 CellCentric: Industry and Academic Collaboration for Drug Development
5.10.10 Constellation Pharmaceuticals
5.10.11 EpiTherapeutics
5.10.12 Epizyme Has Signed Valuable Big Pharma Collaboration Agreements
5.10.13 IkerChem: HDAC and DNMT Inhibitors in Cancer and CNS Disorders
5.10.14 Karus Therapeutics: HDAC Inhibitors for Inflammatory Diseases and Cancer
6. EPIGENETIC DIAGNOSTICS MARKET 2013-2023
6.1 Development of the Epigenetic Diagnostics Market 2013-2023
6.1.1 LDTs vs. IVDs: Two Diagnostic Development Strategies
6.2 Epigenetic Diagnostics Marketed 2012
6.2.1 Epi proColon 2.0 (Epigenomics)
6.2.1.1 ColoVantage (Quest Diagnostics)
6.2.1.2 Septin9 LDT (ARUP Laboratories)
6.2.2 ColoSure (LabCorp)
6.2.3 ConfirmMDx for Prostate Cancer (MDxHealth)
6.2.3.1 Gene Methylation in Prostate Cancer (LabCorp)
6.2.4 Epi proLung (Epigenomics)
6.2.5 MGMT Gene Methylation Assay (LabCorp)
6.2.6 Bladder Cancer Testing with CertNDx (Predictive Biosciences)
6.3 Epigenetic Diagnostics Pipeline 2012
6.3.1 The Future of Colorectal Cancer Testing
6.3.1.1 Cologuard: Using More Biomarkers to Improve Sensitivity
6.3.1.2 Orion Colorectal Cancer Risk Test (Orion Genomics)
6.3.1.3 PredictMDx (MDxHealth)
6.3.2 New Prognostic Tools in Development for Prostate Cancer
6.3.3 Lung Cancer
6.3.3.1 Lung Cancer Screening Test (Orion Genomics)
6.3.3.2 ConfirmMDx and InformMDx (MDxHealth)
6.3.4 Future Developments in Bladder Cancer Testing
6.3.4.1 Bladder Cancer Screening Test (Orion Genomics)
6.3.5 Other Cancer Tests in Development 2012
6.3.5.1 PredictMDx for Brain Cancer LDT (MDxHealth)
6.3.5.2 Pancreatic Cancer Prognostic Test (PrognosDx Health)
6.4 Leading Epigenetic Diagnostic Developers 2012
6.4.1 Epigenomics Markets Multiple Tests in the EU
6.4.1.1 Low Revenue in the EU 2010-2012
6.4.2 Exact Sciences and Colorectal Cancer Screening
6.4.3 MDxHealth: Targeting the US Diagnostics Market
6.4.3.1 Strong Revenue Growth 2009-2011
6.4.4 Orion Genomics Has Discovered More Than 100 Biomarkers
6.4.5 Predictive Biosciences
6.4.6 PrognosDx Health: Developing Epigenetic Prognostics
7. EPIGENETIC TECHNOLOGIES MARKET 2013-2023
7.1 Epigenetic Technology and Services Market 2013-2023
7.1.1 Outsourcing Epigenetic Discovery and Analysis
7.2 Next Generation Sequencing (NGS)
7.2.1 Lower Costs and Higher Speed for Expanded Research
7.2.2 Bottlenecks in Bioinformatics
7.2.3 Single Molecule Sequencing to Compete with NGS
7.3 Future Developments in Chromatin Immunoprecipitation
7.3.1 Considerations for ChIP-Seq
7.4 Future Developments in Bisulphite Screening
7.4.1 Techniques for Researching 5hmC Developed 2012
7.5 High Throughput Screening for Epigenetics
7.6 Leading Providers of Epigenetic Technologies 2012
7.6.1 Active Motif
7.6.2 Agilent Technologies: Measurement Tools for Epigenetic Research
7.6.3 Diagenode
7.6.4 DiscoveRx: Providing Tools to Research New Epigenetic Pathways
7.6.5 EMD Millipore
7.6.6 Epigentek Specialises in Epigenetic Technologies and Services
7.6.7 Epiontis: Epigenetics in Regenerative Medicine
7.6.8 Life Technologies: Cutting the Cost of NGS
7.6.9 Qiagen is Developing Epigenetic Technologies and Diagnostics
7.6.10 Roche
8. RESEARCH AND PRODUCT DEVELOPMENT STRATEGIES IN EPIGENETICS 2013-2023
8.1 The Epigenetic Therapies and Technologies Market by Disease 2013-2023
8.2 Present and Future Epigenetic Research in Cancer
8.2.1 Twin Studies Reveal Epigenetic Biomarkers in Breast Cancer
8.2.2 Colorectal Cancer: Beyond Two Well-Established Biomarkers
8.2.3 Prognostic Markers in Lung Cancer
8.2.4 Prostate Cancer: Advances in Diagnostics, but Little Progress in Epigenetic Therapies
8.3 DNA Hypomethylation in Autoimmune Diseases
8.3.1 Lupus
8.3.2 Rheumatoid Arthritis as a Target for Drug and Diagnostic Development
8.3.2.1 Case Study: Ignyta, Pioneering Epigenetic Diagnostics in Rheumatoid Arthritis
8.3.3 Diabetes Incidence is Linked to Ageing and Diet
8.4 Neurodegenerative Diseases
8.4.1 Alzheimer's Disease: Alleviation of Symptoms Using HDAC Inhibitors
8.4.2 Huntington's Disease: Epigenetic Drugs Approaching Clinical Development
8.5 Neurological Disorders
8.5.1 Drug Resistance in Schizophrenia
8.5.2 Autism is Linked to Many Genetic and Epigenetic Mutations
8.6 New Epigenetic Drug Targets
8.6.1 BET Proteins Are a Target in Many Therapeutic Areas
8.6.2 Assessing and Understanding DNA Hydroxymethylation
8.6.3 Sirtuins as an Underexploited HDAC Inhibitor Class
8.6.4 Histone Methyltransferase
8.6.4.1 Lysine Methyltransferase
8.6.4.2 Case Study: Domainex Developing HMT Inhibitors
8.6.4.3 Protein Arginine Methyltransferases: Overcoming Insufficient Potency
8.6.5 Lysine Demethylases Show Promise as Targets for Cancer Therapies
9. EPIGENETIC THERAPIES AND TECHNOLOGIES: INDUSTRY TRENDS 2013-2023
9.1 Epigenetic Therapies and Technologies Market: Strengths and Weaknesses 2011-2012
9.1.1 Understanding Epigenetic Markers and Mechanisms
9.1.2 Specificity of Current Epigenetic Therapies
9.2 Epigenetic Therapies and Technologies Market: Opportunities and Threats 2013-2023
9.2.1 The Importance of Translational Research
9.2.2 Developing Companion Diagnostics
9.2.3 Long Therapeutic and Diagnostic Pipelines
9.2.4 Combination Therapy with Epigenetic Drugs
9.2.5 Epigenetic Therapies to Overcome Drug Resistance
9.2.6 Drug Targets Beyond HDAC and DNMT Inhibition
9.3 Epigenetic Therapies and Technologies: STEP Analysis 2013-2023
9.4 Social Factors Influencing Product Development
9.4.1 Epigenetics and the Environment
9.4.2 Epigenetics, Ageing, and Disease
9.4.2.1 Rising Global Disease Incidence to Drive Epigenetics Market Growth
9.4.3 Targeting Orphan Indications and Patient Subpopulations
9.4.4 Epigenetics Can Lead to Personalised and Stratified Medicine
9.5 Technological Developments to Aid Epigenetic Research
9.5.1 Next-Generation Sequencing Improving Epigenetic Research
9.5.2 Using Epigenetics to Drive Forward Stem Cell Research
9.5.3 Complementary and Competing Technologies
9.5.3.1 Genomics
9.5.3.2 Proteomics
9.5.3.3 Metabolomics: A Comparatively New Discipline
9.6 Economic Factors
9.6.1 The Cost of Epigenetic Research
9.6.2 The Role of Big Pharma in the Epigenetics Market 2013-2023
9.6.2.1 Pfizer
9.6.2.2 Novartis: Performing Epigenetic Research in China
9.6.2.3 GSK Has Signed Many Deals in Epigenetics
9.6.3 Major Licensing Deals in Epigenetics
9.6.4 Epigenetic Business Models
9.7 Political Issues
9.7.1 Ethics in Epigenetic Research
9.7.2 Collaboration in Epigenetic Research
9.7.2.1 Structural Genomics Consortium
9.7.2.2 NIH Roadmap Epigenetics Project
9.7.2.3 International Human Epigenome Consortium
9.7.2.4 Blueprint: Contributing to Global Epigenome Libraries
10. RESEARCH INTERVIEWS
10.1 Dr James Rusche, SVP R&D, Repligen
10.1.1 The Advantage in Using HDAC Inhibitors
10.1.2 Combination Therapy Using HDAC Inhibitors
10.1.3 Challenges in Developing Epigenetic Drugs
10.1.3.1 Challenges Specific to Selective HDAC Inhibitors
10.1.4 Partnering for Epigenetic Drug Development
10.2 Dr Simon Kerry, CEO, Karus Therapeutics
10.2.1 Differences in Developing Selective and pan-HDAC Inhibitors
10.2.2 HDAC Inhibitors for Cancer and Other Diseases
10.2.3 Comparison of Kinase Inhibitor and HDAC Inhibitor Development
10.2.4 The Future of Epigenetic R&D
11. CONCLUSIONS FROM OUR STUDY
11.1 Drugs Account for Most Epigenetic Revenues in 2012
11.2 Growth Expected in All Sectors of the Epigenetics Market 2013-2023
11.2.1 Developed Markets to Dominate 2013-2023
11.3 Many Opportunities Exist for Market Entry
1.1 Epigenetic Therapies and Technologies: World Market Review
1.2 Report Contents
1.3 Research and Analysis Methods
2. AN INTRODUCTION TO EPIGENETICS
2.1 How is Epigenetics Defined?
2.1.1 Epigenetic Mechanisms
2.1.2 A Brief History of Epigenetic Research
2.2 The Links between Epigenetics and Disease
2.2.1 The Role of Lifestyle in Epigenetics
2.2.2 Epigenetics and Cancer
2.2.3 Epigenetics in Inherited Disorders
2.2.4 Epigenetics in Neurological Diseases
2.3 Epigenetics for Disease Diagnosis
2.3.1 Diagnosing for Breast Cancer
2.3.2 Colorectal Cancer: The Importance of Early Diagnosis
2.3.3 Diagnostics for Lung Cancer: Difficulty in Accessing Samples
2.3.4 Diagnostics for Prostate Cancer
2.4 The Use of Epigenetics in Treating Disease
2.4.1 DNA Methyltransferase (DNMT) Inhibitors
2.4.1.1 Myelodysplastic Syndromes (MDS)
2.4.2 Histone Deacetylase (HDAC) Inhibitors
2.4.2.1 Cutaneous T Cell Lymphoma (CTCL)
2.4.2.2 Peripheral T Cell Lymphoma (PTCL)
2.5 Drug Discovery and Development Tools Using Epigenetics
2.5.1 Bisulphite Screening for DNA Methylation
2.5.2 Chromatin Immunoprecipitation (ChIP) for Histone Modification
3. THE EPIGENETIC THERAPIES AND TECHNOLOGIES MARKET 2013-2023
3.1 The Epigenetic Therapies and Technologies Market 2011-2012
3.1.1 Leading Sectors of the Market 2011-2012
3.2 The Epigenetic Therapies and Technologies Market 2013-2023
3.2.1 The Epigenetic Therapies and Technologies Market: Overall Revenue Forecast 2013-2023
3.2.2 What Will Drive Revenue Growth for Epigenetic Therapies and Technologies?
3.2.3 Rising Importance for Diagnostics Revenue 2013-2023
3.3 Epigenetic Therapies Submarket 2013-2023
3.3.1 Epigenetic Therapies Submarket: Revenue Forecast 2013-2023
3.3.2 Factors Influencing Epigenetic Therapy Uptake and Revenues 2013-2023
3.4 Epigenetic Technologies Submarket 2013-2023
3.4.1 Epigenetic Technologies Submarket: Revenue Forecast 2013-2023
3.4.2 Epigenetic Technologies Submarket: Drivers and Restraints 2013-2023
3.5 Epigenetic Diagnostics Submarket 2013-2023
3.5.1 Epigenetic Diagnostics Submarket: Revenue Forecast 2013-2023
3.5.2 New Product Launches to Drive Growth 2013-2023
4. LEADING NATIONAL EPIGENETIC THERAPY AND TECHNOLOGY MARKETS 2013-2023
4.1 Leading National Markets for Epigenetic Therapies and Technologies 2011-2012
4.2 Leading National Markets: Revenue Forecasts 2013-2023
4.2.1 The Continued Dominance of Western Markets 2013-2023
4.3 The North American Market 2013-2023
4.3.1 The US: The World's Largest Market for Epigenetic Therapies and Technologies 2013-2023
4.3.2 Canada: Revenues 2013-2023
4.4 The European Market 2011-2012
4.4.1 Leading National Markets in Europe: Revenue Forecasts 2013-2023
4.4.2 Germany: Revenues 2013-2023
4.4.3 The UK: A Leading Market for Epigenetics Research
4.5 Japan: Recent Entry of the Epigenetic Therapies Market
4.6 Epigenetics in Emerging Markets
4.6.1 BRIC Nations: Rising Importance for Epigenetic Therapies and Technologies 2013-2023
5. EPIGENETIC THERAPIES MARKET 2013-2023
5.1 Changes to the Epigenetic Therapies Market 2013-2023
5.2 Vidaza: The First Epigenetic Therapy Approved
5.2.1 Vidaza: Strong Revenue Growth 2004-2011
5.2.2 Development as a Combination Therapy to Drive Growth
5.2.3 Vidaza: Revenue Forecast 2013-2023
5.3 Dacogen
5.3.1 Revenue Performance 2004-2011
5.3.2 Approval in the EU in 2012 to Drive Revenue Growth
5.3.3 Dacogen: Revenue Forecast 2013-2023
5.4 Zolinza
5.4.1 Zolinza as a Potential Treatment for Multiple Myeloma
5.4.2 Zolinza: Revenue Forecast 2013-2023
5.5 Istodax
5.5.1 US PTCL Approval
5.5.2 Istodax: Revenue Forecast 2013-2023
5.6 Rich Pipeline for HDAC Inhibitors in 2012
5.6.1 Belinostat: A Selective HDAC Inhibitor for PTCL
5.6.2 Faridak for Velcade-Refractory Multiple Myeloma
5.6.3 Entinostat (Syndax Pharmaceuticals)
5.6.4 Resminostat (4SC)
5.6.5 Pracinostat: The First Epigenetic Therapy Developed in Singapore
5.6.6 Mocetinostat Has Been Tested in More Than 12 Clinical Trials
5.6.7 Quisinostat (Centocor Research & Development)
5.6.8 Rocilinostat (Acetylon Pharmaceuticals)
5.6.9 CHR-3996 (Chroma Therapeutics)
5.6.10 Givinostat for Cancer, Autoimmune and Neurodegenerative Diseases
5.6.11 SHP-141 (Shape Pharmaceuticals)
5.6.12 EVP-0334 (EnVivo Pharmaceuticals/MethylGene)
5.6.13 4SC-202 (4SC)
5.6.14 Tefinostat (Chroma Therapeutics)
5.6.15 CXD101 (Celleron Therapeutics)
5.6.16 Repligen: Epigenetic Therapies for Orphan Neurodegenerative Indications
5.6.17 Abexinostat (Pharmacyclics/Servier)
5.7 DNMT Inhibitor Pipeline 2012
5.7.1 SGI-110: A Second Generation DNMT Inhibitor
5.8 Pipeline Treatments Targeting Other Epigenetic Enzymes 2012
5.8.1 EPZ-5676: The First Clinical-Stage HMT Inhibitor
5.8.2 Oryzon Genomics: Targeting LSD1
5.8.3 Salarius Pharmaceuticals
5.8.4 Resverlogix Advancing BET Protein Inhibitors
5.9 MiRNA Therapy Pipeline 2012
5.9.1 Miravirsen (Santaris Pharma) is the Only Clinical-Stage miRNA Therapy
5.9.2 MRX34 (Mirna Therapeutics)
5.9.3 Regulus Therapeutics Is Collaborating with Big Pharma Players
5.10 Leading Epigenetic Therapy Manufacturers and Developers 2012
5.10.1 Celgene: Market Leader 2011-2012
5.10.2 Eisai
5.10.3 Merck & Co.
5.10.4 TopoTarget: Assessing Drug Commercialisation Strategies
5.10.5 Syndax Pharmaceuticals
5.10.6 4SC
5.10.7 Astex Pharmaceuticals is an Experienced Epigenetic Therapy Developer
5.10.8 Curis is Developing Multi-Targeted Therapies
5.10.9 CellCentric: Industry and Academic Collaboration for Drug Development
5.10.10 Constellation Pharmaceuticals
5.10.11 EpiTherapeutics
5.10.12 Epizyme Has Signed Valuable Big Pharma Collaboration Agreements
5.10.13 IkerChem: HDAC and DNMT Inhibitors in Cancer and CNS Disorders
5.10.14 Karus Therapeutics: HDAC Inhibitors for Inflammatory Diseases and Cancer
6. EPIGENETIC DIAGNOSTICS MARKET 2013-2023
6.1 Development of the Epigenetic Diagnostics Market 2013-2023
6.1.1 LDTs vs. IVDs: Two Diagnostic Development Strategies
6.2 Epigenetic Diagnostics Marketed 2012
6.2.1 Epi proColon 2.0 (Epigenomics)
6.2.1.1 ColoVantage (Quest Diagnostics)
6.2.1.2 Septin9 LDT (ARUP Laboratories)
6.2.2 ColoSure (LabCorp)
6.2.3 ConfirmMDx for Prostate Cancer (MDxHealth)
6.2.3.1 Gene Methylation in Prostate Cancer (LabCorp)
6.2.4 Epi proLung (Epigenomics)
6.2.5 MGMT Gene Methylation Assay (LabCorp)
6.2.6 Bladder Cancer Testing with CertNDx (Predictive Biosciences)
6.3 Epigenetic Diagnostics Pipeline 2012
6.3.1 The Future of Colorectal Cancer Testing
6.3.1.1 Cologuard: Using More Biomarkers to Improve Sensitivity
6.3.1.2 Orion Colorectal Cancer Risk Test (Orion Genomics)
6.3.1.3 PredictMDx (MDxHealth)
6.3.2 New Prognostic Tools in Development for Prostate Cancer
6.3.3 Lung Cancer
6.3.3.1 Lung Cancer Screening Test (Orion Genomics)
6.3.3.2 ConfirmMDx and InformMDx (MDxHealth)
6.3.4 Future Developments in Bladder Cancer Testing
6.3.4.1 Bladder Cancer Screening Test (Orion Genomics)
6.3.5 Other Cancer Tests in Development 2012
6.3.5.1 PredictMDx for Brain Cancer LDT (MDxHealth)
6.3.5.2 Pancreatic Cancer Prognostic Test (PrognosDx Health)
6.4 Leading Epigenetic Diagnostic Developers 2012
6.4.1 Epigenomics Markets Multiple Tests in the EU
6.4.1.1 Low Revenue in the EU 2010-2012
6.4.2 Exact Sciences and Colorectal Cancer Screening
6.4.3 MDxHealth: Targeting the US Diagnostics Market
6.4.3.1 Strong Revenue Growth 2009-2011
6.4.4 Orion Genomics Has Discovered More Than 100 Biomarkers
6.4.5 Predictive Biosciences
6.4.6 PrognosDx Health: Developing Epigenetic Prognostics
7. EPIGENETIC TECHNOLOGIES MARKET 2013-2023
7.1 Epigenetic Technology and Services Market 2013-2023
7.1.1 Outsourcing Epigenetic Discovery and Analysis
7.2 Next Generation Sequencing (NGS)
7.2.1 Lower Costs and Higher Speed for Expanded Research
7.2.2 Bottlenecks in Bioinformatics
7.2.3 Single Molecule Sequencing to Compete with NGS
7.3 Future Developments in Chromatin Immunoprecipitation
7.3.1 Considerations for ChIP-Seq
7.4 Future Developments in Bisulphite Screening
7.4.1 Techniques for Researching 5hmC Developed 2012
7.5 High Throughput Screening for Epigenetics
7.6 Leading Providers of Epigenetic Technologies 2012
7.6.1 Active Motif
7.6.2 Agilent Technologies: Measurement Tools for Epigenetic Research
7.6.3 Diagenode
7.6.4 DiscoveRx: Providing Tools to Research New Epigenetic Pathways
7.6.5 EMD Millipore
7.6.6 Epigentek Specialises in Epigenetic Technologies and Services
7.6.7 Epiontis: Epigenetics in Regenerative Medicine
7.6.8 Life Technologies: Cutting the Cost of NGS
7.6.9 Qiagen is Developing Epigenetic Technologies and Diagnostics
7.6.10 Roche
8. RESEARCH AND PRODUCT DEVELOPMENT STRATEGIES IN EPIGENETICS 2013-2023
8.1 The Epigenetic Therapies and Technologies Market by Disease 2013-2023
8.2 Present and Future Epigenetic Research in Cancer
8.2.1 Twin Studies Reveal Epigenetic Biomarkers in Breast Cancer
8.2.2 Colorectal Cancer: Beyond Two Well-Established Biomarkers
8.2.3 Prognostic Markers in Lung Cancer
8.2.4 Prostate Cancer: Advances in Diagnostics, but Little Progress in Epigenetic Therapies
8.3 DNA Hypomethylation in Autoimmune Diseases
8.3.1 Lupus
8.3.2 Rheumatoid Arthritis as a Target for Drug and Diagnostic Development
8.3.2.1 Case Study: Ignyta, Pioneering Epigenetic Diagnostics in Rheumatoid Arthritis
8.3.3 Diabetes Incidence is Linked to Ageing and Diet
8.4 Neurodegenerative Diseases
8.4.1 Alzheimer's Disease: Alleviation of Symptoms Using HDAC Inhibitors
8.4.2 Huntington's Disease: Epigenetic Drugs Approaching Clinical Development
8.5 Neurological Disorders
8.5.1 Drug Resistance in Schizophrenia
8.5.2 Autism is Linked to Many Genetic and Epigenetic Mutations
8.6 New Epigenetic Drug Targets
8.6.1 BET Proteins Are a Target in Many Therapeutic Areas
8.6.2 Assessing and Understanding DNA Hydroxymethylation
8.6.3 Sirtuins as an Underexploited HDAC Inhibitor Class
8.6.4 Histone Methyltransferase
8.6.4.1 Lysine Methyltransferase
8.6.4.2 Case Study: Domainex Developing HMT Inhibitors
8.6.4.3 Protein Arginine Methyltransferases: Overcoming Insufficient Potency
8.6.5 Lysine Demethylases Show Promise as Targets for Cancer Therapies
9. EPIGENETIC THERAPIES AND TECHNOLOGIES: INDUSTRY TRENDS 2013-2023
9.1 Epigenetic Therapies and Technologies Market: Strengths and Weaknesses 2011-2012
9.1.1 Understanding Epigenetic Markers and Mechanisms
9.1.2 Specificity of Current Epigenetic Therapies
9.2 Epigenetic Therapies and Technologies Market: Opportunities and Threats 2013-2023
9.2.1 The Importance of Translational Research
9.2.2 Developing Companion Diagnostics
9.2.3 Long Therapeutic and Diagnostic Pipelines
9.2.4 Combination Therapy with Epigenetic Drugs
9.2.5 Epigenetic Therapies to Overcome Drug Resistance
9.2.6 Drug Targets Beyond HDAC and DNMT Inhibition
9.3 Epigenetic Therapies and Technologies: STEP Analysis 2013-2023
9.4 Social Factors Influencing Product Development
9.4.1 Epigenetics and the Environment
9.4.2 Epigenetics, Ageing, and Disease
9.4.2.1 Rising Global Disease Incidence to Drive Epigenetics Market Growth
9.4.3 Targeting Orphan Indications and Patient Subpopulations
9.4.4 Epigenetics Can Lead to Personalised and Stratified Medicine
9.5 Technological Developments to Aid Epigenetic Research
9.5.1 Next-Generation Sequencing Improving Epigenetic Research
9.5.2 Using Epigenetics to Drive Forward Stem Cell Research
9.5.3 Complementary and Competing Technologies
9.5.3.1 Genomics
9.5.3.2 Proteomics
9.5.3.3 Metabolomics: A Comparatively New Discipline
9.6 Economic Factors
9.6.1 The Cost of Epigenetic Research
9.6.2 The Role of Big Pharma in the Epigenetics Market 2013-2023
9.6.2.1 Pfizer
9.6.2.2 Novartis: Performing Epigenetic Research in China
9.6.2.3 GSK Has Signed Many Deals in Epigenetics
9.6.3 Major Licensing Deals in Epigenetics
9.6.4 Epigenetic Business Models
9.7 Political Issues
9.7.1 Ethics in Epigenetic Research
9.7.2 Collaboration in Epigenetic Research
9.7.2.1 Structural Genomics Consortium
9.7.2.2 NIH Roadmap Epigenetics Project
9.7.2.3 International Human Epigenome Consortium
9.7.2.4 Blueprint: Contributing to Global Epigenome Libraries
10. RESEARCH INTERVIEWS
10.1 Dr James Rusche, SVP R&D, Repligen
10.1.1 The Advantage in Using HDAC Inhibitors
10.1.2 Combination Therapy Using HDAC Inhibitors
10.1.3 Challenges in Developing Epigenetic Drugs
10.1.3.1 Challenges Specific to Selective HDAC Inhibitors
10.1.4 Partnering for Epigenetic Drug Development
10.2 Dr Simon Kerry, CEO, Karus Therapeutics
10.2.1 Differences in Developing Selective and pan-HDAC Inhibitors
10.2.2 HDAC Inhibitors for Cancer and Other Diseases
10.2.3 Comparison of Kinase Inhibitor and HDAC Inhibitor Development
10.2.4 The Future of Epigenetic R&D
11. CONCLUSIONS FROM OUR STUDY
11.1 Drugs Account for Most Epigenetic Revenues in 2012
11.2 Growth Expected in All Sectors of the Epigenetics Market 2013-2023
11.2.1 Developed Markets to Dominate 2013-2023
11.3 Many Opportunities Exist for Market Entry
LIST OF TABLES
Table 1.1 Currency Exchange Rates, 2011
Table 2.1 Selected Enzymes Involved in Epigenetic Mechanisms
Table 2.2 Selected Treatments for MDS, 2012
Table 3.1 Epigenetic Therapies and Technologies Market by Sector, 2011
Table 3.2 Epigenetic Therapies and Technologies Market: Overall Market and Revenue Forecasts by Sector, 2011-2023
Table 3.3 Epigenetic Therapies and Technologies Market: Drivers and Restraints, 2013-2023
Table 3.4 Epigenetic Therapies and Technologies Submarket Shares, 2011-2023
Table 3.5 Epigenetic Therapies Submarket by Drug, 2011
Table 3.6 Epigenetic Therapies Submarket: Overall Submarket and Revenue Forecasts by Drug, 2011-2023
Table 3.7 Epigenetic Therapies Submarket: Drivers and Restraints, 2013-2023
Table 3.8 Epigenetic Technologies Submarket: Revenue Forecast, 2011-2023
Table 3.9 Epigenetic Technologies Submarket: Drivers and Restraints, 2013-2023
Table 3.10 Epigenetic Diagnostics Submarket: Revenue Forecast, 2011-2023
Table 3.11 Epigenetic Diagnostics Submarket: Drivers and Restraints, 2013-2023
Table 4.1 Epigenetic Therapies and Technologies Market by Country, 2011
Table 4.2 Epigenetic Therapies and Technologies in Developed Markets: Drivers and Restraints, 2013-2023
Table 4.3 Epigenetic Therapies and Technologies Market: Revenue Forecasts by Country, 2011-2023
Table 4.4 Epigenetic Therapies and Technologies in Emerging Markets: Drivers and Restraints, 2013-2023
Table 4.5 Epigenetic Therapies and Technologies: Market Shares by Country, 2011-2023
Table 4.6 US Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Table 4.7 Canadian Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Table 4.8 European Epigenetic Therapies and Technologies Market by Country, 2011
Table 4.9 Selected Epigenetic Companies Headquartered in the EU, 2012
Table 4.10 European Epigenetic Therapies and Technologies Market: Revenue Forecasts by Leading Country, 2011-2023
Table 4.11 German Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Table 4.12 UK Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Table 4.13 Japanese Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Table 4.14 BRIC Nations (Grouped) Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Table 5.1 Epigenetic Therapies Submarket: Drug Revenue Shares, 2011-2023
Table 5.2 Vidaza: Revenue, 2004-2011
Table 5.3 Vidaza: Revenue by Region, H1 2011-2012
Table 5.4 Vidaza: Revenue Forecast, 2011-2023
Table 5.5 Vidaza: Drivers and Restraints, 2013-2023
Table 5.6 Dacogen: Revenue and Royalty Revenue, 2006-2011
Table 5.7 Dacogen: Phase III Clinical Trials, 2012
Table 5.8 Dacogen: Drivers and Restraints, 2013-2023
Table 5.9 Dacogen: Revenue Forecast, 2011-2023
Table 5.10 Zolinza: Drivers and Restraints, 2013-2023
Table 5.11 Zolinza: Revenue Forecast, 2011-2023
Table 5.12 Istodax: Revenue, 2010-2011
Table 5.13 CTCL and PTCL Prevalence by Region
Table 5.14 Istodax: Drivers and Restraints, 2013-2023
Table 5.15 Istodax: Revenue Forecast, 2011-2023
Table 5.16 Selected HDAC Inhibitors in Development, 2012
Table 5.17 NCI Sponsored Trials of Belinostat, 2012
Table 5.18 Belinostat: Revenue Forecast, 2014-2023
Table 5.19 Faridak: Revenue Forecast, 2014-2023
Table 5.20 Drug Mechanisms Being Assessed in Clinical Trials for Breast Cancer and Multiple Myeloma, 2012
Table 5.21 Selected Pipeline for Other Epigenetic Enzyme Inhibitors, 2012
Table 5.22 Selected MiRNA Therapy Pipeline, 2012
Table 5.23 CellCentric's Research Institution Affiliations, 2012
Table 5.24 IkerChem Epigenetic Pipeline, 2012
Table 6.1 Pipeline and Marketed Epigenetic Colorectal Cancer Test Comparison, 2012
Table 6.2 Epigenomics: Revenue, 2010-2011
Table 6.3 MDxHealth: Pipeline, 2012
Table 6.4 MDxHealth: Revenue by Source, 2009-2011
Table 7.1 Fall in Average Cost of Sequencing the Human Genome, 2000-2012
Table 7.2 Selected Producers of Single-Molecule Sequencing Technologies, 2012
Table 7.3 Life Technologies: Revenue by Sector, 2010-2011
Table 8.1 Epigenetic Therapies and Technologies Market by Disease, 2011
Table 8.2 Prevalence of Cancers Targeted by Epigenetic Therapies, 2012
Table 9.1 Epigenetic Therapies and Technologies Market: Strengths and Weaknesses, 2011-2012
Table 9.2 Epigenetic Therapies and Technologies Market: Opportunities and Threats, 2013-2023
Table 9.3 Epigenetic Therapies and Technologies Market: STEP Analysis, 2013-2023
Table 9.4 Biomarker Development and Technologies Market Discipline, 2011
Table 9.5 Lucrative Licensing Deals for Epigenetic Therapies, 2011-2012
Table 9.6 Selected University Spin-Outs in the Epigenetics Industry, 1997-2011
Table 9.7 IHEC Member Organisations, 2012
Table 11.1 Epigenetic Therapies and Technologies Market by Sector, 2011-2023
Table 11.2 Epigenetic Therapies and Technologies Market by Region, 2011-2023
Table 1.1 Currency Exchange Rates, 2011
Table 2.1 Selected Enzymes Involved in Epigenetic Mechanisms
Table 2.2 Selected Treatments for MDS, 2012
Table 3.1 Epigenetic Therapies and Technologies Market by Sector, 2011
Table 3.2 Epigenetic Therapies and Technologies Market: Overall Market and Revenue Forecasts by Sector, 2011-2023
Table 3.3 Epigenetic Therapies and Technologies Market: Drivers and Restraints, 2013-2023
Table 3.4 Epigenetic Therapies and Technologies Submarket Shares, 2011-2023
Table 3.5 Epigenetic Therapies Submarket by Drug, 2011
Table 3.6 Epigenetic Therapies Submarket: Overall Submarket and Revenue Forecasts by Drug, 2011-2023
Table 3.7 Epigenetic Therapies Submarket: Drivers and Restraints, 2013-2023
Table 3.8 Epigenetic Technologies Submarket: Revenue Forecast, 2011-2023
Table 3.9 Epigenetic Technologies Submarket: Drivers and Restraints, 2013-2023
Table 3.10 Epigenetic Diagnostics Submarket: Revenue Forecast, 2011-2023
Table 3.11 Epigenetic Diagnostics Submarket: Drivers and Restraints, 2013-2023
Table 4.1 Epigenetic Therapies and Technologies Market by Country, 2011
Table 4.2 Epigenetic Therapies and Technologies in Developed Markets: Drivers and Restraints, 2013-2023
Table 4.3 Epigenetic Therapies and Technologies Market: Revenue Forecasts by Country, 2011-2023
Table 4.4 Epigenetic Therapies and Technologies in Emerging Markets: Drivers and Restraints, 2013-2023
Table 4.5 Epigenetic Therapies and Technologies: Market Shares by Country, 2011-2023
Table 4.6 US Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Table 4.7 Canadian Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Table 4.8 European Epigenetic Therapies and Technologies Market by Country, 2011
Table 4.9 Selected Epigenetic Companies Headquartered in the EU, 2012
Table 4.10 European Epigenetic Therapies and Technologies Market: Revenue Forecasts by Leading Country, 2011-2023
Table 4.11 German Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Table 4.12 UK Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Table 4.13 Japanese Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Table 4.14 BRIC Nations (Grouped) Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Table 5.1 Epigenetic Therapies Submarket: Drug Revenue Shares, 2011-2023
Table 5.2 Vidaza: Revenue, 2004-2011
Table 5.3 Vidaza: Revenue by Region, H1 2011-2012
Table 5.4 Vidaza: Revenue Forecast, 2011-2023
Table 5.5 Vidaza: Drivers and Restraints, 2013-2023
Table 5.6 Dacogen: Revenue and Royalty Revenue, 2006-2011
Table 5.7 Dacogen: Phase III Clinical Trials, 2012
Table 5.8 Dacogen: Drivers and Restraints, 2013-2023
Table 5.9 Dacogen: Revenue Forecast, 2011-2023
Table 5.10 Zolinza: Drivers and Restraints, 2013-2023
Table 5.11 Zolinza: Revenue Forecast, 2011-2023
Table 5.12 Istodax: Revenue, 2010-2011
Table 5.13 CTCL and PTCL Prevalence by Region
Table 5.14 Istodax: Drivers and Restraints, 2013-2023
Table 5.15 Istodax: Revenue Forecast, 2011-2023
Table 5.16 Selected HDAC Inhibitors in Development, 2012
Table 5.17 NCI Sponsored Trials of Belinostat, 2012
Table 5.18 Belinostat: Revenue Forecast, 2014-2023
Table 5.19 Faridak: Revenue Forecast, 2014-2023
Table 5.20 Drug Mechanisms Being Assessed in Clinical Trials for Breast Cancer and Multiple Myeloma, 2012
Table 5.21 Selected Pipeline for Other Epigenetic Enzyme Inhibitors, 2012
Table 5.22 Selected MiRNA Therapy Pipeline, 2012
Table 5.23 CellCentric's Research Institution Affiliations, 2012
Table 5.24 IkerChem Epigenetic Pipeline, 2012
Table 6.1 Pipeline and Marketed Epigenetic Colorectal Cancer Test Comparison, 2012
Table 6.2 Epigenomics: Revenue, 2010-2011
Table 6.3 MDxHealth: Pipeline, 2012
Table 6.4 MDxHealth: Revenue by Source, 2009-2011
Table 7.1 Fall in Average Cost of Sequencing the Human Genome, 2000-2012
Table 7.2 Selected Producers of Single-Molecule Sequencing Technologies, 2012
Table 7.3 Life Technologies: Revenue by Sector, 2010-2011
Table 8.1 Epigenetic Therapies and Technologies Market by Disease, 2011
Table 8.2 Prevalence of Cancers Targeted by Epigenetic Therapies, 2012
Table 9.1 Epigenetic Therapies and Technologies Market: Strengths and Weaknesses, 2011-2012
Table 9.2 Epigenetic Therapies and Technologies Market: Opportunities and Threats, 2013-2023
Table 9.3 Epigenetic Therapies and Technologies Market: STEP Analysis, 2013-2023
Table 9.4 Biomarker Development and Technologies Market Discipline, 2011
Table 9.5 Lucrative Licensing Deals for Epigenetic Therapies, 2011-2012
Table 9.6 Selected University Spin-Outs in the Epigenetics Industry, 1997-2011
Table 9.7 IHEC Member Organisations, 2012
Table 11.1 Epigenetic Therapies and Technologies Market by Sector, 2011-2023
Table 11.2 Epigenetic Therapies and Technologies Market by Region, 2011-2023
Dacogen: Revenue Forecast 2013-2023
Early in the forecast period, revenue growth for Dacogen will be driven by increased uptake in the EU, following approval in 2012. However, this growth may be restrained by decisions from cost effectiveness bodies in the region determining that the clinical benefit of Dacogen in AML does not outweigh the cost. The launch in the EU will drive revenue to a peak of $373m in 2015. Success in the US safety trial and reassessment by the FDA for treating AML patients may also act as a driver for growth. Outside the US, strong revenue growth will be maintained as a result of patent protection until the end of the forecast period. However, patents in the US begin to expire in 2013, allowing generic competition to enter.
As with Vidaza, this generic competition may be slow to launch. However, as they have similar modes of action, both Vidaza and Dacogen will be affected by the launch of generics of each other. In addition, both drugs will be negatively impacted by the launch of SGI-110 towards the middle of this decade. Revenue for Dacogen will be more severely affected as SGI-110 is a second generation version of that drug. Doctors will therefore be encouraged to switch patients directly from Dacogen to SGI-110.
